Pfizer Kills $160 Billion Deal With Allergan Amid Crackdown On Corporate Inversions The multibillion dollar deal between Pfizer and Allergan is off the table. The new corporate inversion rules of the IRS and the Treasury Department may have a hand on it. by Milafel Dacanay
Business Tech IHS And Markit To Form Ultimate Data Provider: Here's A Closer Look At The $13 Billion Merger by Kyle Nofuente